Answers are grounded in this paper and cite their sources.
Evaluating the cost-effectiveness of newer anesthetic agents requires a comprehensive assessment of total costs, including personnel and operational efficiency, rather than just drug acquisition costs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
White et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: